Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0C9ZW
|
|||
Drug Name |
PMID25656651-Compound-26a
|
|||
Drug Type |
Small molecular drug
|
|||
Structure |
Download2D MOL |
|||
Formula |
C22H15F3N6
|
|||
Canonical SMILES |
C1=CC(=CC(=C1)C(F)(F)F)CNC2=NC=C3C4=C(C=NC=C4)NC5=C(C3=N2)C=CC=N5
|
|||
InChI |
1S/C22H15F3N6/c23-22(24,25)14-4-1-3-13(9-14)10-28-21-29-11-17-15-6-8-26-12-18(15)30-20-16(19(17)31-21)5-2-7-27-20/h1-9,11-12H,10H2,(H,27,30)(H,28,29,31)
|
|||
InChIKey |
BJNZVGIKBDSXJO-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [1] |
Target's Patent Info | Fusion protein Bcr-Abl (Bcr-Abl) | Target's Patent Info | [1] |
References | Top | |||
---|---|---|---|---|
REF 1 | Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.